Association between metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction subtypes and risk of colorectal cancer: A prospective cohort study - 24/03/25
Highlights |
• | MASLD is associated with an increased risk of colorectal cancer development. |
• | The risk of colorectal cancer rises with an increasing number of coexisting metabolic dysfunction in MASLD participants. |
• | Lean-MASLD and diabetes-MASLD participants may be high risk group of colorectal cancer risk. |
Abstract |
Background |
To evaluate the association between a new definition of metabolic dysfunction-associated steatotic liver disease (MASLD), different metabolic dysfunction subtypes and risk of colorectal cancer(CRC).
Methods |
A total of 99,979 participants who met the criteria were included from the Kailuan Study. Participants were categorized into three groups based on fatty liver disease and metabolic status: Non-SLD with metabolic normal group(NMN), Non-SLD with metabolic abnormal group(NMA) and MASLD group. Incident of CRC were confirmed by review of medical records. The Cox proportional hazard regression models were used to assess the association MASLD with the risk of CRC by calculating the hazard ratios (HR) and 95 % confidence interval (CI).
Results |
During a mean 13.54 ± 2.78 years of follow-up, we documented 669 CRC. Multivariate Cox regression analysis showed that compared with the NMN group, MASLD participants demonstrated an increased risk of developing CRC (HR 1.54 95 %CI 1.12–2.13). The greater the number of metabolic dysfunctions, the greater the risks of CRC (P < 0.05). The HR for CRC was 1.93 (95 % CI 1.27–2.92) in MASLD participants with 4–5 items of metabolic dysfunctions. In the subtype analysis, the HR for CRC was 1.97 (95 % CI 1.13–3.45) in lean-MASLD participants and 1.55(95 %CI 1.12–2.15) in diabetes-MASLD participants.
Conclusion |
MASLD was associated with increased risk of CRC. Moreover, MASLD individuals who complicated by lean or diabetes have an increased risk of developing CRC.
Le texte complet de cet article est disponible en PDF.Keywords : Metabolic dysfunction-associated steatotic liver disease, Colorectal cancer, Cohort study, Lean-MASLD, MASLD with diabetes
Plan
| Disclosure summary: The authors have nothing to disclose. |
|
| The authors declare no potential conflict of interest. |
Vol 49 - N° 5
Article 102573- mai 2025 Retour au numéro
Article précédent
- Emergent endoscopy is associated with lower mortality in hemodynamically unstable upper GI bleeding: Single-center experience with 24/7 endoscopy services
- Thuan Thi-Minh Pham, Duc Trong Quach, Ly Thi-Kim Le, Vy Ngoc-Tuong Nguyen, Ngoc My Chung, Linh Xuan Tran, Quang Dinh Le, Cong Hong-Minh Vo
- Relative dose intensity of gemcitabine-nab-paclitaxel combination as second-line or more in locally advanced or metastatic pancreatic adenocarcinoma
- Adrien Grancher, Leila Tagemouati, André Gillibert, Lilian Schwarz, Virginie Vernon, David Sefrioui, Pierre Michel, Marie Dutherage, Frédéric Di Fiore
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?